Clario Announces Investment in New Translation Service Technology to Reduce Start-up Times for eCOA Studies and Increase Global Patient Access to Clinical Trials

Leading Clinical Trial Endpoint Technology Provider Sets Ambitious Goals to Reduce Translation Time by 20-30% Through Investment in New Technology and Processes

PHILADELPHIA CREAM, August 12, 2022 /PRNewswire/ — Clariona technology company that provides leading endpoint technology solutions for decentralized, hybrid and onsite clinical trials (DCTs), today announced an investment in a new translation service technology – Clario Translation Workbench – to reduce translation by 20 to 30%, which will accelerate Launch of the eCOA study and increased global patient access to clinical trials.

“Our customers need to deploy studies in multiple countries and ensure that patients have access to accurate and timely translations of their electronic clinical outcome assessments. This is essential for a successful study. With Clario’s global reach and this investment in technology and processes to reduce translation times, we can help increase patient access and accelerate overall study setup times,” said Andy CooperEVP eCOA and trial activation.

The translation workshop:

  • Use new technologies to reduce the time spent in communications between the translation provider and Clario
  • Reduce the tedious processes associated with generating accurate screenshots and translations of related screens on eCOA applications
  • Reduce defects and minimize human error with investments in automation and a new centralized data platform

Clients need reliable translation services to initiate studies in multiple countries and reach a diverse patient population. However, they often face delays and challenges related to the technical nature of the work. One of the primary goals of the investment is to reduce the number of manual steps often required in the complex, technical process of delivering accurate translations. Clario’s new Translation Workbench technology was developed and released to directly address these issues.

About Clario

For nearly 50 years, Clarion provides leading endpoint technology solutions for clinical trials. With experience gained from more than 19,000 delivered clinical trials supporting 870 regulatory approvals, Clario fuses scientific expertise and global scale into the broadest technology platform to enable pharmaceutical partners , biotechnology and medical devices to transform lives. Clario Trial Anywhere™ The solutions have powered hybrid and decentralized clinical trials (DCTs) for more than 15 years, enabling sponsors to collect high-quality endpoint data from any modality or location, while improving patient experience. patient. Clario has 30 installations in nine countries across North America, Europe and Asia Pacific.

SOURCEClario

About Joan Dow

Check Also

Baker McKenzie advises Pacoma on the sale to Legget & Platt | Writing

Baker McKenzie advised Pacoma Holding S.à rl in connection with the sale of the Pacoma …